11 Results for "

retinal lesions

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "retinal lesions" in MCE Product Catalog:

  • Categories Recommended:
    More
6
6 Cited Publications
Cat. No.: HY-B1745
CAS No.: 85-87-0
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B1745A
CAS No.: 524-36-7
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
loading...
    loading...
Cat. No.: HY-P10936A
Target:  

Aquaporin

AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. AQP4 (201-220) TFA can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .
loading...
    loading...
Cat. No.: HY-148457
CAS No.: 1613641-69-2
Synonyms: Izervay
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .
loading...
    loading...
Cat. No.: HY-P10936
CAS No.: 2104700-59-4
Target:  

Aquaporin

AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .
loading...
    loading...
Cat. No.: HY-B1745R
CAS No.: 85-87-0
Pyridoxylamine (Standard) is the analytical standard of Pyridoxylamine. This product is intended for research and analytical applications. Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
loading...
    loading...
Cat. No.: HY-178919
CAS No.: 2996841-28-0
N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa .
loading...
    loading...
Cat. No.: HY-B1745AR
CAS No.: 524-36-7
Pyridoxylamine (dihydrochloride) (Standard) is the analytical standard of Pyridoxylamine (dihydrochloride). This product is intended for research and analytical applications. Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
loading...
    loading...
Cat. No.: HY-184141
CAS No.: 3037217-70-9
Target:  

VEGFR

Research Areas:  

Neurological Disease

EYE1090 is an orally active VEGFR2 inhibitor with an IC50 of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .
loading...
    loading...
Cat. No.: HY-182372
CAS No.: 1638153-78-2
Target:  

Epoxide Hydrolase

Research Areas:  

Neurological Disease

SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization .
loading...
    loading...
Cat. No.: HY-184142
CAS No.: 3037217-73-2
Target:  

VEGFR

EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization .
loading...
    loading...
  • 1